Business Wire

c-LEcta Reports Record Year With Significant Growth

Share

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully continued its dynamic business development in fiscal year 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005406/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

c-LEcta Reports Record Year With Significant Growth (Picture: Die Filmagentur)

“We are very proud of our performance in recent years. Our products have provided good growth momentum, but also great resilience due to the diverse use cases and this has supported us over the last two years. To continue to drive this growth in the long term, we have continued to build our team this year and are now pleased to have 120 highly qualified employees on board. We plan to continue to invest in additional staff and equipment in the future, as well,” commented Thomas Pfaadt, CFO of c-LEcta GmbH.

The EXCiPACT certification of c-LEcta’s high quality standards in production and distribution was a highlight of the past year. The requirements for these certifications go beyond those of ISO 9001 and represents an international seal of approval that guarantees the highest quality standards for pharmaceutical excipients and other critical input materials in the pharmaceutical industry. The certification confirmed the high quality standards of c-LEcta and reduces the effort for customers regarding supplier audits in the future.

The product NuCLEANase, a specially optimized enzyme preparation that cleaves all types of DNA, was launched in October 2021. This can be used to remove DNA residues from products manufactured by using microorganisms such as enzymes for the food and feed industries. NuCLEANase was already in high demand at the time of its sales launch, which only underscores its great market potential.

“NuCLEANase is an impressively diverse product with great potential. However, the development also demonstrates the versatility of our ENESYZ technology platform, which allows enzyme developments based on different production systems for a wide range of applications. ENESYZ is constantly being further developed: This year, for example, we were able to integrate an additional expression host, Bacillus, into our enzyme engineering platform,” commented Dr. Marc Struhalla, founder and CEO of c-LEcta.

The company also made significant progress in the area of machine learning and artificial intelligence in 2021. “We have recently achieved some very promising results in this innovative area. The topic is an increasingly important building block for our future product developments. We are rapidly expanding our expertise in this area to defend our technology leadership in enzyme engineering,” said Dr. Struhalla.

c-LEcta is already globally positioned, with approximately 97% of sales now generated abroad. In total, c-LEcta now serves over 400 customers in more than 40 countries. The company has concluded supply contracts for enzyme products with many customers in the pharmaceutical sector, and many customers have approved c-LEcta as a supplier. Long-term customer relationships can thus be established in future areas such as gene and cell therapy. In addition to Europe, mainly North America and Asia play an important role.

c-LEcta’s most important markets, the food and pharmaceutical industries, are subject to strict regulations worldwide. Two enzyme dossiers were submitted by c-LEcta in May 2021. These enzyme dossiers for the food industry complement the company’s offering to its customers, who thus no longer have to worry separately about approvals for the use of the enzymes. By submitting a master file to the FDA, c-LEcta supports its customers from the pharmaceutical industry in terms of regulatory compliance and demonstrates the quality of its manufacturing processes and products.

In October, c-LEcta secured its own building complex with over 10,000 m2 in the new BioSquare, which is to be built at the “Alte Messe” site in Leipzig starting in the second quarter of 2022. “We want to and will continue to grow. Great new facilities for the life science industry are being built at Alte Messe, which will allow us to provide state-of-the-art office and laboratory space for our growing team,” Dr Struhalla said.

A milestone in c-LEcta’s company history was reached in February 2022, when Kerry Group acquired a majority stake in the company. Kerry Group is the world’s leading sustainable nutrition company and is a taste and nutrition partner for the food, beverage and pharmaceutical markets.

Since the acquisition of the majority shareholding, Kerry and c-LEcta have been working closely on numerous projects including the joint global distribution of the DENARASE and NuCLEANase products and have identified new areas of development for the food industry. c-LEcta’s unique enzyme engineering competences and its experience in strain development with Bacillus will be of particular benefit.

“The biotechnology industry has received strong media attention since the outbreak of the COVID-19 pandemic and also significant inflows of funds. c-LEcta also had a record year and has now gained a strong partner in Kerry Group. Their global presence in the food and pharmaceutical sectors gives c-LEcta access to additional markets. Kerry Group brings broad expertise in ingredient technologies and applications, making them a perfect fit for us to better exploit our growth potential in the future. We will continue to work with our current industry partners and, of course, manufacture and distribute our products for our valued customers,” explained Dr Struhalla.

About c-LEcta

c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. Product development is based on the proprietary enzyme technology platform ENESYZ® and is carried out both in-house and in close cooperation with industry partners worldwide. c-LEcta supplies its products to more than 400 customers in over 40 countries. c-LEcta currently employs more than 120 people at its headquarters in Leipzig.

c-LEcta is part of the Kerry Group. Kerry is the world’s leading taste and nutrition partner for the food, beverage and pharmaceutical markets. The company employs 22,000 people across over 150 locations and uses its broad range of ingredient solutions to innovate with its customers and create great tasting products, with improved nutrition and functionality, while ensuring a better impact for the planet.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

cometis AG
Lukas Oftring
Phone: +49 (0) 611 - 205855 - 36
Fax: +49 (0) 611 - 205855 - 66
E-mail: oftring@cometis.de

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ikotek Expands Executive Management Team to Continue Rapid Growth of Its ODM Services Across North America and EMEA Regions29.9.2022 15:00:00 CEST | Press release

Ikotek, the leading IoT original design manufacturer (ODM) and electronics manufacturing service (EMS) provider, is announcing expansion of its executive management team with industry veterans and continue their aggressive growth plans for the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005870/en/ Ikotek - Your Trusted IoT ODM Partner (Photo: Business Wire) Headquartered in San Diego, USA, Ikotek offers a one-stop-shop for IoT solutions across design and development, hardware build, testing and verification, product validation, software development, manufacturing and certification delivering high quality products and services to reduce complexity, speed up time to market, eliminate risk and reduce costs. The company has already designed, manufactured and shipped millions of IoT devices since its inception. Ikotek, the only US-based global ODM with a pure IoT focus, combines end-to-end design consultancy acr

Norway comes top in Arthur D. Little’s Global Electric Mobility Readiness Index29.9.2022 14:52:00 CEST | Press release

Arthur D. Little (ADL) has published the latest edition of its Global Electric Mobility Readiness Index – GEMRIX 2022 – which details how favourable different markets are around the world to electric vehicle (EV) adoption. One of its key findings is that the country most ready for widespread EV uptake is Norway. GEMRIX 2022 has been produced to assist EV decision makers and track global EV uptake. Based on a detailed analysis of key market drivers and using standardized evaluation metrics, GEMRIX 2022 details the readiness of 15 countries for electric mobility. A GEMRIX score of 100 and higher means that it’s equally beneficial to buy and operate an EV as an internal combustion engine (ICE)-based vehicle – with a score of 115, Norway is the only country where this is currently the case. The rest of the benchmarked countries can be broadly categorised into three clusters according to their level of readiness for EV adoption: China, Germany, UK and Singapore are Ambitious Followers, with

Winning Again! FEELM Max Awarded the Golden Leaf Award for "Most Promising Innovation"29.9.2022 14:45:00 CEST | Press release

FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won the Golden Leaf Award for "Most Promising Innovation" at the 2022 Global Tobacco and Nicotine Forum (GTNF) in Washington, DC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005491/en/ GTNF event site (Photo: Business Wire) “Using FEELM’s updated ceramic coil technology, the FEELM Max offers improved flavor consistency, more puffs and reduced harshness through smaller aerosol particles. Most importantly, the FEELM Max offers greater potential for harm reduction,” the organizer of GTNF announced at the award ceremony. Four years ago, FEELM tech won the Golden Leaf Award. And four years later, FEELM Max won the Golden Leaf Award again, it is also FEELM Max's second global award this year after winning the Red Dot Award. The Golden Leaf Award is one of the most prestigious awards in the sector and is des

S64 Bolsters Pioneering Team With Strategic Hires Amid Surging Demand for Private Markets Products29.9.2022 14:05:00 CEST | Press release

S64, the trusted alternatives partner to the world’s leading asset managers and private banks, has today announced a series of strategic hires following a period of rapid growth since its launch in 2020. S64’s best-in-class team, who worked together for over a decade at Deutsche Bank, has further strengthened its expertise by making a number of appointments from blue-chip institutions to its London office. The business also has plans to advance its footprint across EMEA, Asia and Australia in major global financial hubs. Strategic hires following rapid growth Led by founder and CEO Tarun Nagpal, S64’s team has led the way in industry innovation for more than a decade, pioneering the development of alternative platform solutions. The latest additions include Venkata Kota, Head of Client Solutions, formerly of Goldman Sachs and Deutsche Bank; Richard Marland, Head of Operations and Fund Governance, formerly of Deutsche Bank; Tetyana Turek, Business and Project Management, formerly of Deu

Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies29.9.2022 14:00:00 CEST | Press release

As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies. The initiative will draw on UNITAR’s expertise in training and education toward the development of innovative solutions to global challenges and Takeda’s deep knowledge of rare disease and the plasma ecosystem. Global demand for plasma has greatly increased over the past 20 years and is continuing to grow due to increasing numbers of patients with rare diseases being diagnosed, as well as higher standards of care and broader access to treatment globally. This demand for life-changing and life-sustaining plasma-derived therapies far exceeds available supply, resulting in more people around the w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom